Canada’s Drug Agency (CDA‑AMC) has recommended conditional reimbursement for AbbVie’s antibody‑drug conjugate ELAHERE (mirvetuximab soravtansine) for patients with folate‑receptor‑alpha positive, platinum‑resistant ovarian, fallopian‑tube, or primary peritoneal cancer who have received one to three prior systemic therapies.
The recommendation follows the Phase 3 MIRASOL trial, which showed a 35 % reduction in risk of disease progression and a 33 % reduction in risk of death versus chemotherapy, with an overall response rate of 42 % compared to 16 % for chemotherapy.
The decision is conditional, allowing patients to access ELAHERE under Canada’s public drug plans. The recommendation is part of CDA‑AMC’s Target Zero initiative, which accelerated the review process and enabled submission for reimbursement 180 days before Health Canada’s approval.
AbbVie’s oncology portfolio accounted for more than 12 % of total revenue in Q1 2025. In Q4 2024, ELAHERE generated $148 million in sales, and the company expects the Canadian reimbursement to add significant revenue to its oncology segment, which generated $1.543 billion in Q1 2024 and $1.512 billion in Q3 2023.
AbbVie’s management highlighted the importance of the Canadian reimbursement as a key milestone in expanding ELAHERE’s market presence in North America and supporting the company’s strategy to grow its oncology franchise beyond its core immunology products.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.